http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 10 Mar 2026 06:03:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Mar+08/26134789.html si-local-file:///var/storage/secattach/20260310/26134789.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Mar+08/26134789.html Tue, 10 Mar 2026 06:03:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Mar+08/26134789.html si-local-file:///var/storage/secattach/20260310/26134789.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Mar+08/26134789.html Tue, 10 Mar 2026 06:03:00 -0400 ANTX O.53806153 http://www.streetinsider.com/Equity+Offerings/AN2+Therapeutics+raises+%2440+million+in+private+placement/26128697.html <p>AN2 Therapeutics Inc. (NASDAQ: ANTX) announced it entered into a securities purchase agreement for a private placement expected to generate approximately $40 million in gross proceeds before fees and expenses.</p> <p>The clinical-stage biopharmaceutical company is selling 8,245,611 shares of common stock at $2.85 per share and pre-funded warrants to purchase up to 5,789,493 shares at $2.84999 per warrant. The pre-funded warrants have an exercise price of $0.00001 per share and are exercisable immediately until exercised in full, subject to ownership limitations.</p> <p>Participants in the private placement include Coastlands Capital, Commodore Capital, Vivo Capital and other institutional investors. The transaction is expected to http://www.streetinsider.com/Equity+Offerings/AN2+Therapeutics+raises+%2440+million+in+private+placement/26128697.html Mon, 09 Mar 2026 07:00:26 -0400 A.36817542 ANTX O.25213119 O.53806153 http://www.streetinsider.com/Equity+Offerings/AN2+Therapeutics+raises+%2440+million+in+private+placement/26128697.html <p>AN2 Therapeutics Inc. (NASDAQ: ANTX) announced it entered into a securities purchase agreement for a private placement expected to generate approximately $40 million in gross proceeds before fees and expenses.</p> <p>The clinical-stage biopharmaceutical company is selling 8,245,611 shares of common stock at $2.85 per share and pre-funded warrants to purchase up to 5,789,493 shares at $2.84999 per warrant. The pre-funded warrants have an exercise price of $0.00001 per share and are exercisable immediately until exercised in full, subject to ownership limitations.</p> <p>Participants in the private placement include Coastlands Capital, Commodore Capital, Vivo Capital and other institutional investors. The transaction is expected to http://www.streetinsider.com/Equity+Offerings/AN2+Therapeutics+raises+%2440+million+in+private+placement/26128697.html Mon, 09 Mar 2026 07:00:26 -0400 A.36817542 ANTX O.25213119 O.53806153 http://www.streetinsider.com/Equity+Offerings/AN2+Therapeutics+raises+%2440+million+in+private+placement/26128697.html <p>AN2 Therapeutics Inc. (NASDAQ: ANTX) announced it entered into a securities purchase agreement for a private placement expected to generate approximately $40 million in gross proceeds before fees and expenses.</p> <p>The clinical-stage biopharmaceutical company is selling 8,245,611 shares of common stock at $2.85 per share and pre-funded warrants to purchase up to 5,789,493 shares at $2.84999 per warrant. The pre-funded warrants have an exercise price of $0.00001 per share and are exercisable immediately until exercised in full, subject to ownership limitations.</p> <p>Participants in the private placement include Coastlands Capital, Commodore Capital, Vivo Capital and other institutional investors. The transaction is expected to http://www.streetinsider.com/Equity+Offerings/AN2+Therapeutics+raises+%2440+million+in+private+placement/26128697.html Mon, 09 Mar 2026 07:00:26 -0400 A.36817542 ANTX O.25213119 O.53806153 http://www.streetinsider.com/Equity+Offerings/AN2+Therapeutics+raises+%2440+million+in+private+placement/26128697.html <p>AN2 Therapeutics Inc. (NASDAQ: ANTX) announced it entered into a securities purchase agreement for a private placement expected to generate approximately $40 million in gross proceeds before fees and expenses.</p> <p>The clinical-stage biopharmaceutical company is selling 8,245,611 shares of common stock at $2.85 per share and pre-funded warrants to purchase up to 5,789,493 shares at $2.84999 per warrant. The pre-funded warrants have an exercise price of $0.00001 per share and are exercisable immediately until exercised in full, subject to ownership limitations.</p> <p>Participants in the private placement include Coastlands Capital, Commodore Capital, Vivo Capital and other institutional investors. The transaction is expected to http://www.streetinsider.com/Equity+Offerings/AN2+Therapeutics+raises+%2440+million+in+private+placement/26128697.html Mon, 09 Mar 2026 07:00:26 -0400 A.36817542 ANTX O.25213119 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Announces+%2440+Million+Private+Placement+Financing/26128674.html <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million, before deducting placement agent fees and other expenses. The private placement includes participation from Coastlands Capital, Commodore Capital, Vivo Capital and other new and existing institutional investors. </p><p> In the private placement, AN2 Therapeutics is selling 8,245,611 shares of common stock at a price of $2.85 per share http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Announces+%2440+Million+Private+Placement+Financing/26128674.html Mon, 09 Mar 2026 07:00:00 -0400 A.36817542 ANTX O.25213119 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Announces+%2440+Million+Private+Placement+Financing/26128674.html <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million, before deducting placement agent fees and other expenses. The private placement includes participation from Coastlands Capital, Commodore Capital, Vivo Capital and other new and existing institutional investors. </p><p> In the private placement, AN2 Therapeutics is selling 8,245,611 shares of common stock at a price of $2.85 per share http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Announces+%2440+Million+Private+Placement+Financing/26128674.html Mon, 09 Mar 2026 07:00:00 -0400 A.36817542 ANTX O.25213119 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Announces+%2440+Million+Private+Placement+Financing/26128674.html <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million, before deducting placement agent fees and other expenses. The private placement includes participation from Coastlands Capital, Commodore Capital, Vivo Capital and other new and existing institutional investors. </p><p> In the private placement, AN2 Therapeutics is selling 8,245,611 shares of common stock at a price of $2.85 per share http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Announces+%2440+Million+Private+Placement+Financing/26128674.html Mon, 09 Mar 2026 07:00:00 -0400 A.36817542 ANTX O.25213119 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Announces+%2440+Million+Private+Placement+Financing/26128674.html <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million, before deducting placement agent fees and other expenses. The private placement includes participation from Coastlands Capital, Commodore Capital, Vivo Capital and other new and existing institutional investors. </p><p> In the private placement, AN2 Therapeutics is selling 8,245,611 shares of common stock at a price of $2.85 per share http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Announces+%2440+Million+Private+Placement+Financing/26128674.html Mon, 09 Mar 2026 07:00:00 -0400 A.36817542 ANTX O.25213119 O.53806153 http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Announces+%2440+Million+Private+Placement+Financing/26128674.html <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million, before deducting placement agent fees and other expenses. The private placement includes participation from Coastlands Capital, Commodore Capital, Vivo Capital and other new and existing institutional investors. </p><p> In the private placement, AN2 Therapeutics is selling 8,245,611 shares of common stock at a price of $2.85 per share http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Announces+%2440+Million+Private+Placement+Financing/26128674.html Mon, 09 Mar 2026 07:00:00 -0400 A.36817542 ANTX O.25213119 O.53806153 http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Announces+%2440+Million+Private+Placement+Financing/26128674.html <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million, before deducting placement agent fees and other expenses. The private placement includes participation from Coastlands Capital, Commodore Capital, Vivo Capital and other new and existing institutional investors. </p><p> In the private placement, AN2 Therapeutics is selling 8,245,611 shares of common stock at a price of $2.85 per share http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Announces+%2440+Million+Private+Placement+Financing/26128674.html Mon, 09 Mar 2026 07:00:00 -0400 A.36817542 ANTX O.25213119 O.53806153 http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Announces+%2440+Million+Private+Placement+Financing/26128674.html <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million, before deducting placement agent fees and other expenses. The private placement includes participation from Coastlands Capital, Commodore Capital, Vivo Capital and other new and existing institutional investors. </p><p> In the private placement, AN2 Therapeutics is selling 8,245,611 shares of common stock at a price of $2.85 per share http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Announces+%2440+Million+Private+Placement+Financing/26128674.html Mon, 09 Mar 2026 07:00:00 -0400 A.36817542 ANTX O.25213119 O.53806153 http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Announces+%2440+Million+Private+Placement+Financing/26128674.html <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million, before deducting placement agent fees and other expenses. The private placement includes participation from Coastlands Capital, Commodore Capital, Vivo Capital and other new and existing institutional investors. </p><p> In the private placement, AN2 Therapeutics is selling 8,245,611 shares of common stock at a price of $2.85 per share http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Announces+%2440+Million+Private+Placement+Financing/26128674.html Mon, 09 Mar 2026 07:00:00 -0400 A.36817542 ANTX O.25213119 O.53806153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Mar+03++Filed+by%3A+Williams+Sarah+Joanne/26120838.html si-local-file:///var/storage/secattach/20260305/26120838.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Mar+03++Filed+by%3A+Williams+Sarah+Joanne/26120838.html Thu, 05 Mar 2026 18:55:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Mar+03++Filed+by%3A+Williams+Sarah+Joanne/26120838.html si-local-file:///var/storage/secattach/20260305/26120838.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Mar+03++Filed+by%3A+Williams+Sarah+Joanne/26120838.html Thu, 05 Mar 2026 18:55:00 -0400 ANTX O.53806153 http://www.streetinsider.com/FDA/AN2+Therapeutics+plans+phase+2+trial+for+blood+cancer+drug/26100998.html <p>AN2 Therapeutics Inc. (NASDAQ: ANTX) announced plans to advance its oral drug epetraborole into a Phase 2 study for polycythemia vera, a blood cancer characterized by overproduction of red blood cells.</p> <p>The clinical-stage biopharmaceutical company said the Phase 2 trial is expected to begin in the third quarter of 2026, with potential data readouts as early as the fourth quarter of 2026 and throughout 2027.</p> <p>The company's decision to pursue polycythemia vera is based on data from multiple clinical trials of oral epetraborole in healthy volunteers and non-PV patients. The drug demonstrated consistent, controlled, sustained, and dose-dependent reductions in hematocrit levels across http://www.streetinsider.com/FDA/AN2+Therapeutics+plans+phase+2+trial+for+blood+cancer+drug/26100998.html Tue, 03 Mar 2026 16:00:19 -0400 A.23318087 ANTX O.20409024 O.53806153 http://www.streetinsider.com/FDA/AN2+Therapeutics+plans+phase+2+trial+for+blood+cancer+drug/26100998.html <p>AN2 Therapeutics Inc. (NASDAQ: ANTX) announced plans to advance its oral drug epetraborole into a Phase 2 study for polycythemia vera, a blood cancer characterized by overproduction of red blood cells.</p> <p>The clinical-stage biopharmaceutical company said the Phase 2 trial is expected to begin in the third quarter of 2026, with potential data readouts as early as the fourth quarter of 2026 and throughout 2027.</p> <p>The company's decision to pursue polycythemia vera is based on data from multiple clinical trials of oral epetraborole in healthy volunteers and non-PV patients. The drug demonstrated consistent, controlled, sustained, and dose-dependent reductions in hematocrit levels across http://www.streetinsider.com/FDA/AN2+Therapeutics+plans+phase+2+trial+for+blood+cancer+drug/26100998.html Tue, 03 Mar 2026 16:00:19 -0400 A.23318087 ANTX O.20409024 O.53806153 http://www.streetinsider.com/FDA/AN2+Therapeutics+plans+phase+2+trial+for+blood+cancer+drug/26100998.html <p>AN2 Therapeutics Inc. (NASDAQ: ANTX) announced plans to advance its oral drug epetraborole into a Phase 2 study for polycythemia vera, a blood cancer characterized by overproduction of red blood cells.</p> <p>The clinical-stage biopharmaceutical company said the Phase 2 trial is expected to begin in the third quarter of 2026, with potential data readouts as early as the fourth quarter of 2026 and throughout 2027.</p> <p>The company's decision to pursue polycythemia vera is based on data from multiple clinical trials of oral epetraborole in healthy volunteers and non-PV patients. The drug demonstrated consistent, controlled, sustained, and dose-dependent reductions in hematocrit levels across http://www.streetinsider.com/FDA/AN2+Therapeutics+plans+phase+2+trial+for+blood+cancer+drug/26100998.html Tue, 03 Mar 2026 16:00:19 -0400 A.23318087 ANTX O.20409024 O.53806153 http://www.streetinsider.com/FDA/AN2+Therapeutics+plans+phase+2+trial+for+blood+cancer+drug/26100998.html <p>AN2 Therapeutics Inc. (NASDAQ: ANTX) announced plans to advance its oral drug epetraborole into a Phase 2 study for polycythemia vera, a blood cancer characterized by overproduction of red blood cells.</p> <p>The clinical-stage biopharmaceutical company said the Phase 2 trial is expected to begin in the third quarter of 2026, with potential data readouts as early as the fourth quarter of 2026 and throughout 2027.</p> <p>The company's decision to pursue polycythemia vera is based on data from multiple clinical trials of oral epetraborole in healthy volunteers and non-PV patients. The drug demonstrated consistent, controlled, sustained, and dose-dependent reductions in hematocrit levels across http://www.streetinsider.com/FDA/AN2+Therapeutics+plans+phase+2+trial+for+blood+cancer+drug/26100998.html Tue, 03 Mar 2026 16:00:19 -0400 A.23318087 ANTX O.20409024 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Announces+Plans+to+Advance+Oral+Epetraborole+into+Phase+2+Study+for+Polycythemia+Vera+%28PV%29/26100992.html <p class="bwalignc"> <i>Substantial clinical evidence provides rationale to initiate Phase 2 study in PV</i> </p><p class="bwalignc"> <i>Phase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027</i> </p><p class="bwalignc"> <i>AN2 to host webcast on Wednesday, March 4, 2026 at 9:30am ET/ 6:30am PT</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to expand the development of oral epetraborole into a Phase 2 proof-of-concept clinical study in adults with phlebotomy-dependent polycythemia vera (PV). PV is a http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Announces+Plans+to+Advance+Oral+Epetraborole+into+Phase+2+Study+for+Polycythemia+Vera+%28PV%29/26100992.html Tue, 03 Mar 2026 16:00:00 -0400 A.23318087 ANTX O.20409024 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Announces+Plans+to+Advance+Oral+Epetraborole+into+Phase+2+Study+for+Polycythemia+Vera+%28PV%29/26100992.html <p class="bwalignc"> <i>Substantial clinical evidence provides rationale to initiate Phase 2 study in PV</i> </p><p class="bwalignc"> <i>Phase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027</i> </p><p class="bwalignc"> <i>AN2 to host webcast on Wednesday, March 4, 2026 at 9:30am ET/ 6:30am PT</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to expand the development of oral epetraborole into a Phase 2 proof-of-concept clinical study in adults with phlebotomy-dependent polycythemia vera (PV). PV is a http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Announces+Plans+to+Advance+Oral+Epetraborole+into+Phase+2+Study+for+Polycythemia+Vera+%28PV%29/26100992.html Tue, 03 Mar 2026 16:00:00 -0400 A.23318087 ANTX O.20409024 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Announces+Plans+to+Advance+Oral+Epetraborole+into+Phase+2+Study+for+Polycythemia+Vera+%28PV%29/26100992.html <p class="bwalignc"> <i>Substantial clinical evidence provides rationale to initiate Phase 2 study in PV</i> </p><p class="bwalignc"> <i>Phase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027</i> </p><p class="bwalignc"> <i>AN2 to host webcast on Wednesday, March 4, 2026 at 9:30am ET/ 6:30am PT</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to expand the development of oral epetraborole into a Phase 2 proof-of-concept clinical study in adults with phlebotomy-dependent polycythemia vera (PV). PV is a http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Announces+Plans+to+Advance+Oral+Epetraborole+into+Phase+2+Study+for+Polycythemia+Vera+%28PV%29/26100992.html Tue, 03 Mar 2026 16:00:00 -0400 A.23318087 ANTX O.20409024 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Announces+Plans+to+Advance+Oral+Epetraborole+into+Phase+2+Study+for+Polycythemia+Vera+%28PV%29/26100992.html <p class="bwalignc"> <i>Substantial clinical evidence provides rationale to initiate Phase 2 study in PV</i> </p><p class="bwalignc"> <i>Phase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027</i> </p><p class="bwalignc"> <i>AN2 to host webcast on Wednesday, March 4, 2026 at 9:30am ET/ 6:30am PT</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to expand the development of oral epetraborole into a Phase 2 proof-of-concept clinical study in adults with phlebotomy-dependent polycythemia vera (PV). PV is a http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Announces+Plans+to+Advance+Oral+Epetraborole+into+Phase+2+Study+for+Polycythemia+Vera+%28PV%29/26100992.html Tue, 03 Mar 2026 16:00:00 -0400 A.23318087 ANTX O.20409024 O.53806153 http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Announces+Plans+to+Advance+Oral+Epetraborole+into+Phase+2+Study+for+Polycythemia+Vera+%28PV%29/26100992.html <p class="bwalignc"> <i>Substantial clinical evidence provides rationale to initiate Phase 2 study in PV</i> </p><p class="bwalignc"> <i>Phase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027</i> </p><p class="bwalignc"> <i>AN2 to host webcast on Wednesday, March 4, 2026 at 9:30am ET/ 6:30am PT</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to expand the development of oral epetraborole into a Phase 2 proof-of-concept clinical study in adults with phlebotomy-dependent polycythemia vera (PV). PV is a http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Announces+Plans+to+Advance+Oral+Epetraborole+into+Phase+2+Study+for+Polycythemia+Vera+%28PV%29/26100992.html Tue, 03 Mar 2026 16:00:00 -0400 A.23318087 ANTX O.20409024 O.53806153